Reports

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market: By Cell Type: B-cell ALL, T-cell ALL, Philadelphia chromosome: Positive (Ph+) and negative (Ph-) ALL; By Therapy Type; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics; Competitive Landscape; Industry Events and Developments

Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Outlook

The global acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics market attained a value of USD 2.44 billion in 2020. The market is further expected to grow in the forecast period of 2022-2027 at a CAGR of 4.6% to reach USD 3.2 billion by 2026.

 

Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The rising occurrence of acute lymphoblastic leukaemia (ALL) and the growing initiatives by public and private organisations are among the key factors anticipated to drive the market growth.

 

Market Segmentation

The acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics industry can be broadly categorised based on cell type and therapy type.

 

Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market By Therapy Type

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Based on cell type, the market is segmented into:

  • B-Cell ALL 
  • T-Cell ALL 
  • Philadelphia Chromosome: Positive (Ph+) and Negative (Ph-) ALL

Based on the therapy type, the market is divided into:

  • Chemotherapy
    • Hyper- CVAD Regimen
    • CALGB 8811 Regimen
    • Linker Regimen
    • Nucleoside Inhibitors
    • Others
  • Targeted Therapy
  • Radiation Therapy
  • Stem Cell Transplantation

The EMR report looks into the regional markets of acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

 

Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

The technological progress made in the identification of infected cells is a significant market growth driver. Due to factors such as the capacity to kill leukaemia cells and the prevention of the growth and proliferation of cancer, the chemotherapy segment was leading the market in 2020. Due to the growing prevalence in adults, the B-cell ALL type is projected to be the fastest-growing category in the industry. With the release of Besponsa (inotuzumab ozogamicin) and pipeline drugs such as eryaspase (asparaginase), the United States is anticipated to witness a significant growth in the industry in the coming years.

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics industry, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Erytech Pharma
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc. 
  • Others

The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

REPORT FEATURES DETAILS
Base Year 2020
Historical Period 2017-2021
Forecast Period 2022-2027
Scope of the Report Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Cell Type, Therapy Type, Region
Breakup by Cell Type B-cell ALL, T-cell ALL, Philadelphia chromosome: Positive (Ph+) and negative (Ph-) ALL
Breakup by Therapy Type Chemotherapy, Targeted Therapy, Radiation Therapy, Stem Cell Transplantation
Breakup by Region North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Market Dynamics SWOT, Porter's Five Forces, Key Indicators for Price and Demand
Competitive Landscape Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications
Companies Covered Bristol-Myers Squibb Company, Eisai Co., Ltd., Erytech Pharma, F. Hoffmann-La Roche Ltd, Pfizer Inc., Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface                
2    Report Coverage – Key Segmentation and Scope
3    Report Description  

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Historical Market (2017-2021) 
    8.3    Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Forecast (2022-2027)    
    8.4    Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market by Cell Type
        8.4.1    B-cell ALL
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2017-2021)
            8.4.1.3    Forecast Trend (2022-2027)
        8.4.2    T-cell ALL
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2017-2021)
            8.4.2.3    Forecast Trend (2022-2027)
        8.4.3    Philadelphia Chromosome: Positive (Ph+) and negative (Ph-) ALL
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2017-2021)
            8.4.3.3    Forecast Trend (2022-2027)
    8.5    Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market by Therapy Type
        8.5.1    Chemotherapy
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2017-2021)
            8.5.1.3    Forecast Trend (2022-2027)
            8.5.1.4    Breakup by Chemotherapy Type 
                8.5.1.4.1    Hyper-CVAD Regimen
                8.5.1.4.2    CALGB 8811 Regimen
                8.5.1.4.3    Linker Regimen
                8.5.1.4.4    Nucleoside Inhibitors
                8.5.1.4.5    Others
        8.5.2    Targeted Therapy
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2017-2021)
            8.5.2.3    Forecast Trend (2022-2027)
        8.5.3    Radiation Therapy
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2017-2021)
            8.5.3.3    Forecast Trend (2022-2027)
        8.5.4    Stem Cell Transplantation
            8.5.4.1    Market Share
            8.5.4.2    Historical Trend (2017-2021)
            8.5.4.3    Forecast Trend (2022-2027)
    8.6    Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market by Region
        8.6.1    Market Share
            8.6.1.1    North America
            8.6.1.2    Europe
            8.6.1.3    Asia Pacific
            8.6.1.4    Latin America
            8.6.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2017-2021)
        9.1.2    Forecast Trend (2022-2027)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2017-2021)
        9.2.2    Forecast Trend (2022-2027)
        9.2.3    Breakup by Country
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2017-2021)
        9.3.2    Forecast Trend (2022-2027)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2017-2021)
        9.4.2    Forecast Trend (2022-2027)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2017-2021)
        9.5.2    Forecast Trend (2022-2027)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    Key Indicators for Demand
    10.4    Key Indicators for Price
11    Value Chain Analysis 
12    Competitive Landscape

    12.1    Market Structure
    12.2    Company Profiles
        12.2.1    Bristol-Myers Squibb Company
            12.2.1.1    Company Overview
            12.2.1.2    Product Portfolio
            12.2.1.3    Demographic Reach and Achievements
            12.2.1.4    Certifications
        12.2.2    Eisai Co., Ltd.
            12.2.2.1    Company Overview
            12.2.2.2    Product Portfolio
            12.2.2.3    Demographic Reach and Achievements
            12.2.2.4    Certifications
        12.2.3    Erytech Pharma
            12.2.3.1    Company Overview
            12.2.3.2    Product Portfolio
            12.2.3.3    Demographic Reach and Achievements
            12.2.3.4    Certifications
        12.2.4    F. Hoffmann-La Roche Ltd
            12.2.4.1    Company Overview
            12.2.4.2    Product Portfolio
            12.2.4.3    Demographic Reach and Achievements
            12.2.4.4    Certifications
        12.2.5    Pfizer Inc.  
            12.2.5.1    Company Overview
            12.2.5.2    Product Portfolio
            12.2.5.3    Demographic Reach and Achievements
            12.2.5.4    Certifications
        12.2.6    Others
13    Industry Events and Developments


List of Key Figures and Tables

1.    Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market: Key Industry Highlights, 2017 and 2027 
2.    Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Historical Market: Breakup by Cell Type (USD Billion), 2017-2021
3.    Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Forecast: Breakup by Cell Type (USD Billion), 2022-2027
4.    Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Historical Market: Breakup by Therapy Type (USD Billion), 2017-2021
5.    Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Forecast: Breakup by Therapy Type (USD Billion), 2022-2027
6.    Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Historical Market: Breakup by Region (USD Billion), 2017-2021
7.    Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Forecast: Breakup by Region (USD Billion), 2022-2027
8.    North America Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
9.    North America Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
10.    Europe Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
11.    Europe Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
12.    Asia Pacific Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
13.    Asia Pacific Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
14.    Latin America Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
15.    Latin America Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
16.    Middle East and Africa Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
17.    Middle East and Africa Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
18.    Global Acute Lymphocytic/Lymphoblastic Leukaemia (ALL) Therapeutics Market Structure

Key Questions Answered in the Report

In 2020, the global acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics market attained a value of nearly USD 2.44 billion.

The market is projected to grow at a CAGR of 4.6% between 2021 and 2026.

The market is estimated to witness a healthy growth in the forecast period of 2022-2027 to reach about USD 3.2 billion by 2026.

The major drivers of the industry, such as the growing incidences of acute lymphoblastic leukaemia, initiatives by various public and private organisations to create awareness among people, growing R&D activities, and rapid technological advancements, are expected to aid the market growth.

The development of inotuzumab ozogamicin (Besponsa) and pipeline drugs is the key market trend guiding the growth of the industry.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

B-cell ALL, T-cell ALL, and Philadelphia chromosome- positive (Ph+) and -negative (Ph-) ALL are the significant cell types of acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics in the industry.

Chemotherapy segment is the leading therapy type in the market.

The major players in the industry are Bristol-Myers Squibb Company, Eisai Co., Ltd., Erytech Pharma, F. Hoffmann-La Roche Ltd, and Pfizer Inc., among others.

Analyst Review

The global acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics market attained a value of USD 2.44 billion in 2020, driven by the growing cases of acute lymphoblastic leukaemia and increased clinical trials. Aided by the development of inotuzumab ozogamicin, the market is expected to witness a further growth in the forecast period of 2022-2027, growing at a CAGR of 4.6%. The industry is projected to reach USD 3.2 billion by 2026.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on cell type, the industry can be segmented into B-cell ALL, T-cell ALL, and Philadelphia chromosome- positive (Ph+) and -negative (Ph-) ALL. On the basis of therapy, the chemotherapy segment accounts for the leading share in the industry. The major regional markets for acute lymphocytic/lymphoblastic leukaemia (ALL) therapeutics are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Bristol-Myers Squibb Company, Eisai Co., Ltd., Erytech Pharma, F. Hoffmann-La Roche Ltd, and Pfizer Inc., among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports





NEWSLETTER